Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Acquisitions & Divestments: 2019-2024

Historic Change in Acquisitions & Divestments for Intellia Therapeutics (NTLA) over the last 6 years, with Dec 2024 value amounting to $1.1 billion.

  • Intellia Therapeutics' Change in Acquisitions & Divestments fell 41.94% to $115.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $778.6 million, marking a year-over-year decrease of 17.39%. This contributed to the annual value of $1.1 billion for FY2024, which is 20.27% up from last year.
  • Intellia Therapeutics' Change in Acquisitions & Divestments amounted to $1.1 billion in FY2024, which was up 20.27% from $887.1 million recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Change in Acquisitions & Divestments ranged from a high of $1.1 billion in FY2024 and a low of $262.8 million during FY2020.
  • In the last 3 years, Intellia Therapeutics' Change in Acquisitions & Divestments had a median value of $887.1 million in 2023 and averaged $867.2 million.
  • As far as peak fluctuations go, Intellia Therapeutics' Change in Acquisitions & Divestments fell by 20.12% in 2020, and later soared by 84.78% in 2021.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Change in Acquisitions & Divestments stood at $262.8 million in 2020, then surged by 84.78% to $485.6 million in 2021, then spiked by 33.36% to $647.6 million in 2022, then skyrocketed by 36.99% to $887.1 million in 2023, then grew by 20.27% to $1.1 billion in 2024.